Kraj: Australia
Język: angielski
Źródło: Department of Health (Therapeutic Goods Administration)
bosutinib monohydrate, Quantity: 103.4 mg (Equivalent: bosutinib, Qty 100 mg)
Pfizer Australia Pty Ltd
bosutinib monohydrate
Tablet, film coated
Excipient Ingredients: poloxamer; croscarmellose sodium; povidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350
Oral
30, 28
(S4) Prescription Only Medicine
BOSULIF (bosutinib monohydrate) is indicated for the treatment of chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) chronic myeloid Ieukaemia (CML) in adult patients previously treated with two or more tyrosine kinase inhibitors
Visual Identification: Yellow, oval biconvex, film coated tablets debossed with "Pfizer" on one side and "100" on the other side.; Container Type: Blister Pack; Container Material: PVC/PCTFE (Aclar)/Al; Container Life Time: 48 Months; Container Temperature: Store below 30 degrees Celsius
Licence status A
2014-04-29